CAPR - Capricor Therapeutics Inc Stock Price, Fair Value and News

$13.07+0.17 (+1.32%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CAPR Price Action

Last 7 days

-1.4%

Last 30 days

-30.9%

Last 90 days

158.8%

Trailing 12 Months

192.4%

CAPR RSI Chart

CAPR Valuation

Market Cap

594.3M

Price/Earnings (Trailing)

-17.42

Price/Sales (Trailing)

25.59

Price/Free Cashflow

-15.63

CAPR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CAPR Fundamentals

CAPR Revenue

Revenue (TTM)

23.2M

Rev. Growth (Yr)

-63.44%

Rev. Growth (Qtr)

-43.05%

CAPR Earnings

Earnings (TTM)

-34.1M

Earnings Growth (Yr)

-96.49%

Earnings Growth (Qtr)

-14.15%

CAPR Profitability

Return on Equity

-49.97%

Return on Assets

-36.7%

Free Cashflow Yield

-6.4%

CAPR Investor Care

Shares Dilution (1Y)

47.66%

Diluted EPS (TTM)

-1.02

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	27.1M	27.2M	23.2M	0
2023	5.5M	9.5M	14.0M	25.2M
2022	0	0	1.8M	2.6M
2021	165.4K	319.6K	302.7K	244.9K
2020	960.2K	599.7K	474.5K	310.3K
2019	1.5M	1.5M	1.4M	1.0M
2018	2.2M	1.6M	1.5M	1.7M
2017	3.7M	3.5M	3.1M	2.7M
2016	4.9M	4.8M	4.2M	4.0M
2015	5.5M	5.8M	5.8M	5.5M
2014	1.3M	2.2M	3.4M	4.8M
2013	1.9M	2.1M	2.2M	503.2K
2012	1.5M	1.6M	1.8M	1.9M
2011	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

CEO	Dr. Linda MarbÃƒÆ’Ã‚Â¡n Ph.D.
WEBSITE	capricor.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	74

Capricor Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Capricor Therapeutics Inc? What does CAPR stand for in stocks?

CAPR is the stock ticker symbol of Capricor Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Capricor Therapeutics Inc (CAPR)?

As of Fri Dec 20 2024, market cap of Capricor Therapeutics Inc is 594.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CAPR stock?

You can check CAPR's fair value in chart for subscribers.

Is Capricor Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CAPR is over valued or under valued. Whether Capricor Therapeutics Inc is cheap or expensive depends on the assumptions which impact Capricor Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CAPR.

What is Capricor Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CAPR's PE ratio (Price to Earnings) is -17.42 and Price to Sales (PS) ratio is 25.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CAPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Capricor Therapeutics Inc's stock?

In the past 10 years, Capricor Therapeutics Inc has provided -0.092 (multiply by 100 for percentage) rate of return.